New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
08:11 EDTCGIXCancer Genetics launches CALR mutation analysis test
Cancer Genetics has launched a genetic diagnostic test for detecting mutations in the calreticulin gene. This test helps physicians identify patients with certain types of myeloproliferative neoplasms, which are blood cancers that have the potential to evolve into acute leukemia. CGI is one of the first laboratories in the U.S. to offer this test under both CLIA and NY-State Approvals. Patients with the CALR mutation are understood to have more favorable disease outcomes as well as longer overall survival in comparison to patients who possess other biomarkers. Therefore, the results of the test could have implications in predicting a patient's outlook.
News For CGIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
07:45 EDTCGIXCancer Genetics awarded multimillion dollar clinical trial
Cancer Genetics announced that it has been awarded a multimillion dollar, clinical trial in hematological cancers by a leading biotech company the trial is the largest in the company's history of providing clinical trial and genomic services to global biopharma companies. As part of the agreement, CGI will perform all testing, and provide genomic information and monitoring for CLL patients enrolled in multi-arm, randomized, multicenter, global trials. The CLL trials are expected to contribute up to $6.2M in revenue over several years as patients are selected, treated, and monitored using pathway-specific, targeted therapies, and combination therapies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use